I Have P.A.D.

Text size

Talk to Your Doctor About Treatment Right Away

If you have recently been diagnosed with Peripheral Artery Disease (P.A.D., also known as poor circulation in the legs), you should talk to your doctor as soon as possible about treatment options—including PLAVIX—to reduce your risk of heart attack or stroke associated with P.A.D. Because P.A.D. is a serious condition that more than doubles your risk of a heart attack or stroke.

If you’ve been diagnosed with P.A.D. for a while—maybe weeks, months, or years ago—it’s just as important for you and your doctor to find the right treatment for you. P.A.D. doesn’t go away, and its associated risk of heart attack or stroke doesn’t go away either.

You Can Do Something Starting Today

Don’t make the mistake of ignoring your condition. Many people with Peripheral Artery Disease (P.A.D.), also known as poor circulation in the legs, feel no symptoms at all and may think that means they're fine, so they do nothing. P.A.D. is often called a "silent" condition just because you don't feel any symptoms—like pain or heaviness in the legs—doesn't mean you're not at risk for a future heart attack or stroke. By the time you notice symptoms, your arteries could be up to 60% blocked.

PLAVIX helps keep blood platelets from sticking together and forming clots. So, if you've been diagnosed with P.A.D., talk to your doctor about starting treatment immediately. And be sure to ask if PLAVIX could help reduce your risk for a heart attack or stroke.*

*PLAVIX is not indicated for the treatment of symptoms of P.A.D.

PLAVIX helps reduce risk of a heart attack or stroke
Find out how PLAVIX is proven to work to help reduce the risk of a heart attack or stroke for people like you with Peripheral Artery Disease (P.A.D., also known as poor circulation in the legs).

IMPORTANT SAFETY INFORMATION
Certain genetic factors and some medicines such as Prilosec reduce the effect of PLAVIX leaving you at greater risk for heart attack and stroke. Your doctor may use genetic tests to determine treatment. Don’t stop taking PLAVIX without talking to your doctor as your risk of heart attack or stroke may increase. People with stomach ulcers or conditions that cause bleeding should not use PLAVIX. Taking PLAVIX alone or with some other medicines, including aspirin, may increase bleeding risk which can potentially be life-threatening. So tell your doctor when planning surgery. Tell your doctor all medicines you take, including aspirin, especially if you’ve had a stroke. If fever, unexplained weakness or confusion develops, tell your doctor promptly. These may be signs of TTP, a rare but potentially life-threatening condition, reported sometimes less than 2 weeks after starting PLAVIX.

Click here for US Full Prescribing Information Including BOXED WARNING and Medication Guide

Remember, your doctor is the single best source of information regarding your health. Please consult your doctor if you have any questions about your health or your medicine.

 

What to do next: The Importance of Treatment With an Antiplatelet Medication

Did You Know?

Research shows that people who have P.A.D. face a 4 times greater risk of dying from a heart attack or stroke than the general population and a 2 times greater risk of having a stroke than the general population.

Health-care Professional

You are about to enter a site intended solely for the use of health care professionals. Please certify that you are a health care professional by clicking the button below marked "I Agree," or simply click the button marked "I Do Not Agree" to return to the previous page.

I AgreeI Do Not Agree
 

Share with a friend

*Required Field

*

*

Subject: Information from plavix.com sent to you by a friend

*

Your friend asked us to send you a link to the following article at www.plavix.com

Click the link below to read the full article:
PLAVIX(R) (clopidogrel bisulfate): May Help Protect Against Blood Clot Formation
www.plavix.com

This article was bought to you by www.plavix.com

*
 
 

Share with a friend

Thank you. The requested page has been sent to the email address you provided.

Return to the page you were viewing